Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2011-02-15
2011-02-15
Kishore, Gollamudi S (Department: 1612)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
Reexamination Certificate
active
07887836
ABSTRACT:
This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.
REFERENCES:
patent: 4186183 (1980-01-01), Steck et al.
patent: 4217344 (1980-08-01), Vanlerberghe et al.
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4261975 (1981-04-01), Fullerton et al.
patent: 4485054 (1984-11-01), Mezei et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4603044 (1986-07-01), Geho et al.
patent: 4737323 (1988-04-01), Martin et al.
patent: 4774085 (1988-09-01), Fidler
patent: 4837028 (1989-06-01), Allen
patent: 4885172 (1989-12-01), Bally et al.
patent: 4946787 (1990-08-01), Eppstein et al.
patent: 4952408 (1990-08-01), Rahman
patent: 4957773 (1990-09-01), Spencer et al.
patent: 5059421 (1991-10-01), Loughrey et al.
patent: 5077056 (1991-12-01), Bally et al.
patent: 5165922 (1992-11-01), Hellstrom et al.
patent: 5171578 (1992-12-01), Bally et al.
patent: 5262168 (1993-11-01), Lenk et al.
patent: 5417978 (1995-05-01), Tari et al.
patent: 5543152 (1996-08-01), Webb et al.
patent: 5567592 (1996-10-01), Benet et al.
patent: 5595756 (1997-01-01), Bally et al.
patent: 5648090 (1997-07-01), Rahman et al.
patent: 5714163 (1998-02-01), Forssen et al.
patent: 5736155 (1998-04-01), Bally et al.
patent: 5741516 (1998-04-01), Webb et al.
patent: 5762957 (1998-06-01), Mehlhorn
patent: 5814335 (1998-09-01), Webb et al.
patent: 5820873 (1998-10-01), Choi et al.
patent: 5837282 (1998-11-01), Fenske et al.
patent: 5885613 (1999-03-01), Holland et al.
patent: 5888537 (1999-03-01), Forssen et al.
patent: 6129914 (2000-10-01), Weiner et al.
patent: 6320017 (2001-11-01), Ansell
patent: 6723338 (2004-04-01), Sarris et al.
patent: 7060828 (2006-06-01), Madden et al.
patent: 7094423 (2006-08-01), Maurer et al.
patent: 7244448 (2007-07-01), Madden et al.
patent: 7244450 (2007-07-01), Sarris et al.
patent: 7247316 (2007-07-01), Sarris et al.
patent: 7311924 (2007-12-01), Sarris et al.
patent: 7452550 (2008-11-01), Madden et al.
patent: 2004/0171768 (2004-09-01), Miho
patent: 2006/0008909 (2006-01-01), Cullis et al.
patent: 2006/0093662 (2006-05-01), Madden et al.
patent: 2006/0257465 (2006-11-01), Maurer et al.
patent: 2006/0269594 (2006-11-01), Madden et al.
patent: 2009/0028933 (2009-01-01), Thomas
patent: 89/11292 (1989-11-01), None
patent: 91/17424 (1991-11-01), None
patent: 95/35094 (1995-12-01), None
patent: 96/00057 (1996-01-01), None
patent: 00/59473 (2000-10-01), None
Bedikian, Agop Y. et al., “A pilot study with vincristine dulfate liposome infusion in patients with metastatic melanoma,” Melanoma Research, vol. 18:400-404 (2008).
Bloomfield, Victor A., “Quasi-Elastic Light Scattering Applications in Biochemistry and Biology,” Ann. Rev. Biophys. Bioeng., vol. 10:421-450 (1981).
Bostrom, Bruce C. et al., “Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group,” Blood, vol. 101(10):3809-3817 (2003).
Deamer, D. et al., “Large Volume Liposomes by an Ether Vaporization Method,” Biochimica et Biophysica Acta, vol. 443:629-634 (1976).
Dumontet, Charles et al., “Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death,” Journal of Clinical Oncology, vol. 17(3):1061-1070 (1999).
Fayad, L. et al., “Report of a phase II study of spingosomal vincristine (SV) in patients with relapsed or refractory Hodgkin's disease,” Journal of Clinical Oncology, vol. 23(16S) Poster Session 6624 (2005).
Fraley, Robert T. et al., “Entrapment of a bacterial plasmid in phospholipid vesicles: Potential for gene transfer,” Proc. Natl. Acad. Sci. USA, vol. 76(7):3348-3352 (1979).
Green, Louis S. et al., “Axonal Transport Disturbances in Vincristine-Induced Peripheral Neuropathy,” Ann. Neural., vol. 1:255-262 (1977).
Gruner, Sol M. et al., “Materials Properties of Liposomal Bilayers,” Liposomes—from Biophysics to Therapeutics, Marcel Dekker, Inc., New York, Marc J. Ostro (Ed.) Chpt. 1, pp. 1-38 (1987).
Haim, Nissim et al., “Full Dose Vincristine (without 2-mg Dose Limit) in the Treatment of Lymphomas,” Cancer, vol. 73:2515-2519 (1994).
Heath, T.D. et al., “Covalent Attachment of Immunoglobulins to Liposomes Via Glycosphingolipids,” Biochimica et Biophysica Acta, vol. 640:66-81 (1981).
Hope, M.J. et al., “Generation of Multilamellar and Unilamellar Phospholipid Vesicles,” Chemistry and Physics of Lipids, vol. 40:89-107 (1986).
Hope, M.J. et al., “Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential,” Biochimica et Biophysica Acta, vol. 812:55-65 (1985).
Hudson, W.A. et al., “Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects,” Leukemia, vol. 12:2029-2033 (1998).
Jackson, Don V. et al., “Intravenous Vincristine Infusion: Phase I Trial,” Cancer, vol. 48:2559-2564 (1981).
Jackson, Don V. et al., “Treatment of Advanced Non-Hodgkin's Lymphoma With Vincristine Infusion,” Cancer, vol. 53:2601-2606 (1984).
Kantarjian, Hagop M. et al., “Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen,” Br. J. Haematol., vol. 88(1):94-100 (1994).
Kantarjian, Hagop M. et al., “Experience With Vincristine, Doxorubicin, and Dexamethasone (VAD) Chemotherapy in Adults With Refractory Acute Lymphocytic Leukemia,” Cancer, vol. 64:16-22 (1989).
King, Robert E., “Pharmaceutical Preparations and Their Manufacture,” Remington's Pharmaceutical Sciences, 17th Edition, Mack Publishing Company, Easton, Pennsylvania, Part 8, pp. 1409-1677 (1985).
Kluin-Nelemans, Hanneke C. et al., “A New Non-Hodgkin's B-Cell Line (DoHH2) with a Chromosomal Translocation t(14;18) (q32;q21),” Leukemia, vol. 5(3):221-224 (1991).
Leonetti, Jean-Paul et al., “Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication,” Proc. Natl. Acad. Sci. USA, vol. 87:2448-2451 (1990).
Mayer, L.D. et al., “Vesicles of variable sizes produced by a rapid extrusion procedure,” Biochimica et Biophysica Acta, vol. 858:161-168 (1986).
O'Brien, Susan et al., “A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo (liposomal vincristine sulfate) in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (Ph ALL) in Second Relapse or Who Progressed Following Two Treatment Lines,” 52nd ASH Annual Meeting and Exposition, New Orleans (2009).
Quasthoff, Stefan et al., “Chemotherapy-induced peripheral neuropathy,” J. Neurol., vol. 249:9-17 (2002).
Renneisen, Karin et al., “Inhibition of Expression of Human Immunodeficiency Virus-1 in Vitro by Antibody-targeted Liposomes Containing Antisense RNA to the env Region,” The Journal of Biological Chemistry, vol. 265 (27):16337-16342 (1990).
Rodriguez, Maria Alma et al., “Phase II Study of Sphingosomal Vincristine in CHOP+/− Rituximab for Patients with Aggressive Non-Hodgkin's Lymphoma (NHL):Promising 3 Year Follow-Up Results in Elderly Patients,” Blood, vol. 106, Poster Session 943 (2005).
Rodriguez, M.A. et al., “Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study,” Journal of Clinical Oncology, Proceedings of the 20
Burge Clive T. R.
Cabanillas Fernando
Goldie James H.
Logan Patricia M.
Sarris Andreas H.
Board of Regents , The University of Texas System
Hana Biosciences, Inc.
Kanik Cynthia L.
Kishore Gollamudi S
Nelson Mullins Riley & Scarborough LLP
LandOfFree
Compositions and methods for treating lymphoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating lymphoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating lymphoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2632537